NRXS NeurAxis, Inc. logo

NRXS NeurAxis, Inc.

Healthcare
$7.38-0.67%ClosedMarket Cap: $91.4M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

PEG

P/B

14.06

P/S

21.35

EV/EBITDA

-11.84

DCF Value

$-4.81

FCF Yield

-6.6%

Div Yield

0.0%

Margins & Returns

Gross Margin

85.0%

Operating Margin

-169.9%

Net Margin

-170.1%

ROE

-185.7%

ROA

-83.3%

ROIC

-119.2%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$1.6M$-1.8M$
Q4 null$968.1K$-1.7M$
FY null$3.6M$-7.8M$
Q3 null$811.4K$-2.1M$

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$8.00

Target (Median)

$8.00

Target Range

$8.00 - $8.00

0 Strong Buy2 Buy0 Hold0 Sell0 Strong Sell
Craig-HallumBuy
2026-03-20
Craig-HallumBuy
2025-12-22

Trading Activity

Insider Trades

View All
Aharon Gildirector
SellThu Apr 30
Aharon Gildirector
SellThu Apr 30
Henrichs Timothy Robertofficer: Chief Financial Officer
BuyFri Apr 03
Carrico Thomas Joesephofficer: CRO, CCO, CPO
BuyFri Apr 03
Carrico Brian Allendirector, officer: Chief Executive Officer
BuyFri Apr 03

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

Beta

1.48

NeurAxis, Inc. operates as a neuromodulation therapy device company in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome healthcare companies primarily hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.

Peers